Cargando…
Revisiting Secondary Information Related to Pharmacogenetic Testing
Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guide...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/ https://www.ncbi.nlm.nih.gov/pubmed/34659361 http://dx.doi.org/10.3389/fgene.2021.741395 |
_version_ | 1784583947003363328 |
---|---|
author | Haga, Susanne B. |
author_facet | Haga, Susanne B. |
author_sort | Haga, Susanne B. |
collection | PubMed |
description | Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings. |
format | Online Article Text |
id | pubmed-8517135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85171352021-10-16 Revisiting Secondary Information Related to Pharmacogenetic Testing Haga, Susanne B. Front Genet Genetics Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings. Frontiers Media S.A. 2021-10-01 /pmc/articles/PMC8517135/ /pubmed/34659361 http://dx.doi.org/10.3389/fgene.2021.741395 Text en Copyright © 2021 Haga. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Haga, Susanne B. Revisiting Secondary Information Related to Pharmacogenetic Testing |
title | Revisiting Secondary Information Related to Pharmacogenetic Testing |
title_full | Revisiting Secondary Information Related to Pharmacogenetic Testing |
title_fullStr | Revisiting Secondary Information Related to Pharmacogenetic Testing |
title_full_unstemmed | Revisiting Secondary Information Related to Pharmacogenetic Testing |
title_short | Revisiting Secondary Information Related to Pharmacogenetic Testing |
title_sort | revisiting secondary information related to pharmacogenetic testing |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/ https://www.ncbi.nlm.nih.gov/pubmed/34659361 http://dx.doi.org/10.3389/fgene.2021.741395 |
work_keys_str_mv | AT hagasusanneb revisitingsecondaryinformationrelatedtopharmacogenetictesting |